top of page
Search

SYMPATHOMIMETIC AGENTS: SAR OF SYMPATHOMIMETIC AGENTS

  • Sympathomimetic agents, also known as adrenergic agonists, are a class of drugs that mimic the effects of the sympathetic nervous system.

  • They work by stimulating, or mimicking, the actions of the neurotransmitters epinephrine (adrenaline) and norepinephrine (noradrenaline).

  • These agents can act directly by binding to and activating adrenergic receptors (alpha or beta receptors), or indirectly by increasing the release or inhibiting the reuptake of norepinephrine at nerve endings.

  • Sympathomimetic agents have a wide range of effects, including increasing heart rate and force of contraction (positive inotropic and chronotropic effects), constricting or dilating blood vessels, dilating bronchial tubes, and increasing metabolic rate.

  • Because of their diverse effects, sympathomimetic agents are used in the treatment of numerous health conditions.

Diagram illustrating the Sympathomimetic Agents
Diagram illustrating the Sympathomimetic Agents
Diagram categorizing the Adrenergic Agents
Diagram categorizing the Adrenergic Agents

For example:

Asthma and COPD:

  • Drugs like albuterol and salmeterol (beta-2 adrenergic agonists) are used to dilate the bronchi and bronchioles, decreasing resistance in the respiratory airway and increasing airflow to the lungs.

Cardiac Arrest and Shock:

  • Epinephrine is used to increase heart rate, force of contraction, and cardiac output, which improves blood flow to the body during these emergency situations.

Anaphylaxis:

  • Epinephrine is also used to treat severe allergic reactions due to its ability to constrict blood vessels, relax smooth muscles in the lungs to improve breathing, stimulate the heart, and reduce swelling around the face and lips.

Nasal Congestion:

  • Drugs like phenylephrine are used as decongestants. They constrict the blood vessels in the nasal passages, thereby reducing the swelling and congestion.

However, sympathomimetic agents also have potential side effects, such as hypertension, tachycardia, anxiety, and insomnia, due to their stimulatory effects. They must therefore be used with caution, especially in people with heart disease, hypertension, and anxiety disorders.

STRUCTURE-ACTIVITY RELATIONSHIP (SAR) OF SYMPATHOMIMETIC AGENTS

  • The Structure-Activity Relationship (SAR) describes the connection between a drug's chemical structure and its biological activity.

  • Understanding this relationship helps in the design of compounds with desired properties and minimal side effects.

Diagram illustrating the Structure-Activity Relationship
Diagram illustrating the Structure-Activity Relationship

Here's a basic overview of the SAR for sympathomimetic agents:

1.Basic Structure:

  • Sympathomimetic agents generally contain a catechol or phenylisopropanolamine structure.

  • This consists of a benzene ring with two hydroxyl groups (catechol) or one hydroxyl group (phenylisopropanolamine), an intermediate carbon chain, and an amine group.

2.Substituents on the Benzene Ring:

  • The position and type of substituents on the benzene ring influence the receptor selectivity and metabolic stability of the drug.

  • For example, sympathomimetics with a catechol structure (like epinephrine and norepinephrine) are non-selective but are rapidly metabolized by enzymes COMT and MAO.

  • However, modification of the catechol structure, as in albuterol, can confer beta-2 selectivity and resistance to metabolism.

3.Intermediate Carbon Chain:

  • This part of the molecule influences the receptor selectivity of the drug.

  • A larger chain with bulky substituents tends to favor beta receptor activity, while a smaller chain favors alpha receptor activity.

4.Amine Group:

  • The amine group is vital for activity. It allows the molecule to mimic the natural neurotransmitters norepinephrine and epinephrine, and bind to adrenergic receptors.

  • The state of the amine (whether it's primary, secondary, or tertiary) can also influence receptor selectivity and the ability of the drug to cross the blood-brain barrier.

5.Chirality:

  • Many sympathomimetic drugs contain chiral centers and the stereochemistry can impact the drug's potency.

  • For example, (R)-isomers of albuterol are more potent bronchodilators than the (S)-isomers.

This is a simplified summary and actual drug design involves a more complex understanding of these factors, as well as considerations of the drug's pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body).




Attention!  We are facing some technical difficulties from google end because of which you may see empty blank spaces in between text. Please Ignore them, that does not mean incomplete or missing content. we are working on resolving the issue.  Keep Learning from world's best exam Notes!

bottom of page